对RECIP 1.0的临床实施
Ishita Sen1, Dharmender Malik1, Parul Thakral1
1Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurgaon -122002 Haryana, India.
Seminars in nuclear medicine
|January 10, 2026
概括
在PSMA PET/CT (RECIP 1.0) 中的响应评估标准为使用PSMA PET成像评估前列腺癌治疗响应提供了一个新的标准. 这种框架改进了传统方法,通过结合瘤体积和新病变来更好地预测患者的结果.
科学领域:
- 在瘤学瘤学.
- 核医学是一种核医学.
- 放射学 放射学是一门学科.
背景情况:
- 前列腺癌对全球健康构成重大挑战.
- 先进的前列腺癌治疗已经通过PSMA向的PET成像和放射性体疗法进行了革命.
- 现有的响应评估工具 (PSA动力学,CT,骨扫描,PCWG3,RECIST) 有局限性,包括PSA爆发,无法评估仅骨疾病,以及对早期转移性变化的敏感性低.
研究的目的:
- 引入和验证PSMA PET/CT中响应评估标准 (RECIP 1.0) 作为评估晚期前列腺癌治疗响应的标准化框架.
- 通过利用PSMA PET成像来解决传统评估方法的局限性.
- 为临床试验和常规实践提供一个强大的工具.
主要方法:
- 开发RECIP 1.0,这是一个基于证据的框架,包括PSMA阳性总瘤体积的变化和新病变的出现.
- 治疗反应分层成完全反应,部分反应,稳定疾病或进展性疾病.
- 对整体和无进展生存时间的RECIP 1.0预后值的评估.
- 对常规临床实践可行性和符合量化细分的视觉RECIP方法的评估.
主要成果:
- 在晚期前列腺癌中,RECIP 1.0显示出对整体和无进展生存的强有力的预后价值.
- 该框架使标准化报告成为临床试验的关键.
- 视觉RECIP方法与基于软件的定量细分表现出很好的一致性,提高了可行性.
- 新兴的人工智能工具在简化RECIP实施方面表现有前途.
结论:
- RECIP 1.0提供了一个强大的和临床上有意义的框架,用于评估针对前列腺癌的PSMA向治疗药物的治疗反应.
- 这种标准化的方法改进了传统方法,提供了更好的预后见解.
- 进一步开发,包括人工智能集成,将提高RECIP 1.0在临床实践中的广泛采用和效率.
相关概念视频
01:15Nursing Implementation
Implementation is the execution of the nursing care plan developed during the planning phase.
The five steps to implementing effective nursing care include reassessing the patient, reviewing and revising the existing nursing care plan, organizing the resources and care delivery, anticipating and preventing complications, and implementing nursing interventions.
The five steps to implementing effective nursing care include reassessing the patient, reviewing and revising the existing nursing care plan, organizing the resources and care delivery, anticipating and preventing complications, and implementing nursing interventions.
01:10In Vitro Drug Release Testing: Overview, Development and Validation
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...